Home › Compare › SHMCF vs ABBV
SHMCF yields 0.80% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, SHMCF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SHMCF + ABBV for your $10,000?
Renewi plc provides waste-to-product services. The company operates through Commercial Waste, Mineralz & Water, and Specialities segments. The Commercial Waste segment engages in the collection and treatment of commercial waste in the Netherlands and Belgium; and processing of wood, aggregates, plastics, paper products, and organic waste. The Mineralz & Water segment decontaminates, stabilizes, and re-uses contaminated materials to produce secondary products for the construction industry in the Netherlands and Belgium; processes and cleans bottom ash, fly ash, and other soils; and handles contaminated soils, old road surfaces, industrial waters, sludges, chemical waste, incinerator residues, and packed hazardous waste. The Specialities segment engages in processing of plants that focuses on recycling and diverting specific waste streams, as well as operates waste treatment facilities for the United Kingdom city and county councils; and recycling of waste from electrical and electronic products, and glass. It operates in the United Kingdom, the Netherlands, Belgium, France, Portugal, and Hungary. The company was formerly known as Shanks Group plc and changed its name to Renewi plc in February 2017. Renewi plc was founded in 1880 and is headquartered in Milton Keynes, the United Kingdom.
Full SHMCF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.